Patient-Reported Outcomes and Safety of TYK2 Inhibitors in Psoriasis

In this episode, ‘Patient-Reported Outcomes and Safety of TYK2 Inhibitors in Psoriasis,’ the expert dermatologists explore how therapeutic success is measured beyond objective skin scores. Dr. Mark Lebwohl explains that patient-reported outcomes, particularly the reduction of itch, often improve more rapidly than physical plaques and correlate directly with overall quality of life. Dr. Tina Bhutani-Jacques emphasizes that for patients, the subjective experience of how they feel is often the most critical factor in treatment satisfaction.

The conversation shifts to the practicalities of patient communication regarding safety. Dr. Lebwohl details his approach to explaining the difference between TYK2 inhibitors and traditional JAK inhibitors, noting that he does not burden patients with the boxed warnings associated with JAKs because TYK2 inhibitors lack those specific risks. He stresses that while baseline blood work is a good practice for general health monitoring, TYK2 inhibitors are remarkably safe and do not typically require ongoing laboratory surveillance.

The experts also dive into the debate over mandatory tuberculosis (TB) testing. Dr. Lebwohl discusses a recent critical statement regarding the potential to remove TB screening requirements for certain classes of psoriasis medications, such as IL-17 and IL-23 blockers, which have not shown a signal for TB reactivation. He shares a personal anecdote about the toxicity of TB prophylaxis to highlight why avoiding unnecessary testing in low-endemic areas like the United States could prevent patient harm. Dr. Bhutani-Jacques concludes by praising these advocacy efforts, noting that reducing such barriers represents a significant step toward streamlining real world psoriasis management.

The next episode in this series, ‘Integrating TYK2 Inhibitors into the Psoriasis Treatment Algorithm,’ features the panelists comparing the safety and efficacy of oral TYK2 inhibitors against modern biologics. Dr. Bhutani-Jacques and Dr. Lebwohl discuss the clinical decision-making process for switching therapies and the potential for off-label combination strategies to achieve total skin clearance.